Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.54 (market cap $5.07B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.24. Which is the better fit depends on your goals.
| ACAD | VEA | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | — |
52-Week High | $29.41 | $72.89 |
52-Week Low | $20.06 | $58.19 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
VEA trades at $73.22, up 0.99% with a bullish technical outlook supported by moving averages. The ETF provides diversified exposure to developed international markets excluding the U.S. Recent institutional activity shows mixed sentiment with both new positions and reductions. VEA's low expense ratio of 0.03% and competitive dividend yield remain key advantages for international diversification.
Outlook remains positive for long-term investors seeking international exposure, though near-term technical indicators show potential overbought conditions. Key risks include currency fluctuations and global economic uncertainty. The ETF's cost efficiency and broad diversification support its appeal despite mixed institutional positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
